Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2012
Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00457977 (Pneumococcal Vaccine Response in COPD), which is not on this map. Cited by 27 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pneumococcal Vaccine Response in COPD
Who cites it
27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2017Pooled it
- Pooled it
- Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review.BMC infectious diseases · 2016Pooled it
- Pooled it
- Comparative immune response of Typbar TCV® (typhoid conjugate vaccine) in extremes of age: An Indian experience.Human vaccines & immunotherapeutics · 2025Trial
- Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy.Journal of the International AIDS Society · 2016Trial
- Trial
- Article
- Article
- Invasive pneumococcal disease caused by vaccine serotype 9V in previously immunized adults.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025Article
- Review
- Development of semisynthetic saponin immunostimulants.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2024Review
- Interpretation of the Key Issues of Expert Consensus on Immunomodulatory Therapies for Chronic Obstructive Pulmonary Disease.Journal of translational internal medicine · 2022Article
- Factors influencing acceptance of influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease.Human vaccines & immunotherapeutics · 2022Article
- A comprehensive overview of pneumococcal vaccination recommendations for adults in South Africa, 2022.Journal of thoracic disease · 2022Review
- Vaccination in patients with COPD: COVID has raised the bar.Respirology (Carlton, Vic.) · 2022Article
- Potentiating pneumococcal glycoconjugate vaccine PCV13 with saponin adjuvant VSA-1.Frontiers in immunology · 2022Article
- Update on management of stable chronic obstructive pulmonary disease.Journal of thoracic disease · 2019Review
- Vaccine strategies for prevention of community-acquired pneumonia in Canada: Who would benefit most from pneumococcal immunization?Canadian family physician Medecin de famille canadien · 2019Review
- Measuring immune responses to pneumococcal vaccines.Journal of immunological methods · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 13 institutions in 1 country.
Funding
Abstract
backgroundAlthough the 23-valent pneumococcal polysaccharide vaccine (PPSV23) protects against invasive disease in young healthy persons, randomized controlled trials in chronic obstructive pulmonary disease (COPD) have demonstrated no benefit in the intention-to-treat population. We previously reported that the 7-valent diphtheria-conjugated pneumococcal polysaccharide vaccine (PCV7) is safe and induced greater serotype-specific immunoglobulin G (IgG) and functional antibody than did PPSV23 1 month after vaccination. We hypothesized that these advantages would persist at 1 and 2 years.
methodsOne hundred eighty-one patients with moderate to severe COPD were randomized to receive PPSV23 (n = 90) or PCV7 (1.0 mL; n = 91). We measured IgG by enzyme-linked immunosorbent assay and assessed functional antibody activity by a standardized opsonophagocytosis assay, reported as a killing index (OPK). We determined differences in IgG and OPK between vaccine groups at 1 and 2 years.
resultsRelative to PPSV23, PCV7 induced greater OPK at both 1 and 2 years for 6 of 7 serotypes (not 19F). This response was statistically greater for 5 of 7 serotypes at 1 year and 4 of 7 at 2 years. Comparable differences in IgG were observed but were less often statistically significant. Despite meeting Centers for Disease Control and Prevention criteria for PPSV23 administration, almost 50% of individuals had never been vaccinated. No differences in the frequency of acute exacerbations, pneumonia, or hospitalization were observed.
conclusionsPCV7 induces a greater functional antibody response than PPSV23 in patients with COPD that persists for 2 years after vaccination. This superior functional response supports testing of conjugate vaccination in studies examining clinical end points. CLINICAL TRIALS REGISTRATION: NCT00457977.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.